Table 2 Cancer-specific survival at 12, 36, and 60 months of two groups before and after propensity score matching.
Characteristic | 12-Month | 36-Month | 60-Month | p-value1 |
|---|---|---|---|---|
CSS before PSM | ||||
Overall | 99.9% (99.8%, 99.9%) | 99.5% (99.4%, 99.7%) | 99.1% (98.9%, 99.3%) | |
Lymphadenectomy | 99.8% (99.7%, 99.9%) | 99.4% (99.2%, 99.6%) | 98.8% (98.5%, 99.1%) | 0.003 |
Non-lymphadenectomy | 99.9% (99.9%, 100.0%) | 99.7% (99.5%, 99.8%) | 99.4% (99.2%, 99.6%) | |
CSS after PSM | ||||
Overall | 99.9% (99.8%, 100.0%) | 99.5% (99.4%, 99.7%) | 99.2% (99.0%, 99.4%) | |
Lymphadenectomy | 99.9% (99.8%, 100.0%) | 99.5% (99.3%, 99.7%) | 99.1% (98.8%, 99.4%) | 0.605 |
Non-lymphadenectomy | 99.9% (99.8%, 100.0%) | 99.6% (99.4%, 99.8%) | 99.3% (99.0%, 99.5%) |
